Interim analysis of a phase 1 study of the antibody-drug conjugate SGN-LIV1A in patients with metastatic breast cancer

被引：4
|
作者：
Forero, A.
Burris, H., III
Mita, M.
Specht, J.
Weise, A.
Liu, M. C.
Modi, S.
Pusztai, L.
Kostic, A.
Yang, J.
Li, M.
Hengel, S.
Miller, K.
机构：
[1] Univ Alabama Birmingham, Birmingham, AL USA
[2] Tennessee Oncol, Sarah Cannon Res Inst, Nashville, TN USA
[3] Cedars Sinai Med Ctr, Los Angeles, CA 90048 USA
[4] Univ Washington, Seattle Canc Care Alliance, Seattle, WA 98195 USA
[5] Karmanos Canc Inst, Detroit, MI USA
[6] Mayo Clin, Rochester, MN USA
[7] Mem Sloan Kettering Canc Ctr, New York, NY USA
[8] Yale Univ, Sch Med, New Haven, CT USA
[9] Seattle Genet Inc, Bothell, WA USA
[10] Indiana Univ, Melvin & Bren Simon Canc Ctr, Indianapolis, IN 46204 USA
来源：
CANCER RESEARCH | 2016年 / 76卷
关键词：
D O I：
10.1158/1538-7445.SABCS15-P3-14-05
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
P3-14-05
引用
收藏
页数：2
相关论文
共 50 条
  • [21] Antibody-drug conjugate against breast cancer approved
    不详
    BIOENGINEERED, 2013, 4 (03) : 121 - 121
  • [22] A phase I study of trastuzumab-DM1, a first-in-class HER2 antibody-drug conjugate, in patients with HER2+metastatic breast cancer
    Krop, I. E.
    Beeram, M.
    Modi, S.
    Rabbee, N.
    Girish, S.
    Tibbitts, J.
    Holden, S. N.
    Lutzker, S. G.
    Burris, H. A.
    EJC SUPPLEMENTS, 2007, 5 (04): : 219 - 219
  • [23] A phase II study of trastuzumab-DM1, a first-in-class HER2 antibody-drug conjugate, in patients with HER2+metastatic breast cancer
    Vukelja, S.
    Rugo, H.
    Vogel, C.
    Borson, R.
    Tan-Chiu, E.
    Birkner, M.
    Holden, S. N.
    Klencke, B.
    O'Shaughnessy, J.
    Burris, H. A.
    CANCER RESEARCH, 2009, 69 (02) : 71S - 71S
  • [24] A phase I/II study of CR011-vcMMAE, an antibody-drug conjugate, in patients (pts) with locally advanced or metastatic breast cancer (MBC)
    Peacock, N.
    Saleh, M.
    Bendell, J.
    Rose, A. A.
    Dong, Z.
    Siegel, P. M.
    Crowley, E.
    Simantov, R.
    Vahdat, L.
    JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (15)
  • [25] Trastuzumab emtansine, an antibody-drug conjugate for the treatment of HER2+metastatic breast cancer
    Niculescu-Duvaz, Ion
    CURRENT OPINION IN MOLECULAR THERAPEUTICS, 2010, 12 (03) : 350 - 360
  • [26] Sacituzumab govitecan: a new antibody-drug conjugate for metastatic triple-negative breast cancer
    Banys-Paluchowski, M.
    Krawczyk, Natalia
    ONKOLOGE, 2021, 27 (03): : 287 - 290
  • [27] Advances in Targeted Therapy of Breast Cancer with Antibody-Drug Conjugate
    Subhan, Md Abdus
    Torchilin, Vladimir P.
    PHARMACEUTICS, 2023, 15 (04)
  • [28] Antibody-Drug Conjugate Revolution in Breast Cancer: The Road Ahead
    Grinda, Thomas
    Rassy, Elie
    Pistilli, Barbara
    CURRENT TREATMENT OPTIONS IN ONCOLOGY, 2023, 24 (05) : 442 - 465
  • [29] Computational selection of antibody-drug conjugate targets for breast cancer
    Fauteux, Francois
    Hill, Jennifer J.
    Jaramillo, Maria L.
    Pan, Youlian
    Phan, Sieu
    Famili, Fazel
    O'Connor-McCourt, Maureen
    ONCOTARGET, 2016, 7 (03) : 2555 - 2571
  • [30] A Phase (Ph) I/II Study of CR011-VcMMAE, an Antibody-Drug Conjugate, in Patients (Pts) with Locally Advanced or Metastatic Breast Cancer (MBC).
    Burris, H.
    Saleh, M.
    Bendell, J.
    Hart, L.
    Rose, A. A. N.
    Dong, Z.
    Siegel, P. M.
    Crane, M. F.
    Donovan, D.
    Crowley, E.
    Simantov, R.
    Vahdat, L.
    CANCER RESEARCH, 2009, 69 (24) : 855S - 855S
12345